What is Pictor?
Founded in 2005 by Dr. Anand Kumble and Dr. Sarita Kumble, Pictor is at the forefront of diagnosing complex diseases through a single, small blood sample. The company leverages its proprietary PictArrays technology, enabling multiplex testing for a range of conditions including maternal infections, autoimmune diseases, and hepatitis. With a global presence spanning New Zealand, the USA, Europe, and India, Pictor is actively commercializing its platform, with ongoing development of tests for infectious diseases like COVID-19 and other complex ailments. The company's enterprise-level funding context suggests a mature stage of development, focused on scaling operations and market penetration.
How much funding has Pictor raised?
Pictor has raised a total of $6.1M across 1 funding round:
Unspecified
$6.1M
Unspecified (2022): $6.1M with participation from Marko Bogoievski and K1w1
Key Investors in Pictor
K1w1
K1w1 is an entity operating within the Government sector, based in New Zealand, suggesting a potential focus on public health initiatives or governmental research funding.
Marko Bogoievski
Marko Bogoievski is an individual investor participating in this funding round, likely bringing strategic insights or personal capital to support Pictor's growth.
Undisclosed investor
An undisclosed investor has participated in this funding round, indicating a strategic interest in Pictor's diagnostic technology and market potential.
What's next for Pictor?
The substantial enterprise-level funding positions Pictor for significant expansion and further technological advancement. Future strategies are likely to focus on broadening the portfolio of diagnostic tests, increasing global market reach, and potentially forging strategic partnerships to accelerate adoption of its PictArrays technology. This strategic investment signals confidence in Pictor's ability to address critical unmet needs in disease diagnostics.
See full Pictor company page
